TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25342049

Group type: EXPERIMENTAL
Intervention: Meal 2 (meal 1 mixed with 9 g guar)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Meal 3 (meal 1 divided into 12 equal portions over 60 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Meal 1 (control meal)
Number of subjects: 12
Study: 23833281

Group type: EXPERIMENTAL
Intervention: Phonological awareness
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Orthographic awareness
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Morphological awareness
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Expressive vocabulary
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: RtI status (Tiers 1, 2, & 3)
Number of subjects: 304
Study: 20547947

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 36
Study: 18212755

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1200 mg/m² on days 1 and 8 every 3 weeks for three courses followed by docetaxel 37.5 mg/m² on days 1 and 8 every 3 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Gemcitabine followed by docetaxel
Number of subjects: 56
Study: 16856643

Group type: EXPERIMENTAL
Intervention: Stress management classes
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study: 12696991

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 10920611

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Unjustly untreated group
Number of subjects: 132
Study: 8751518

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion (n = 20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 30
Study: 1434659

Group type: EXPERIMENTAL
Intervention: Early drain removal after 3 days postmastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard drain removal after 6 days postmastectomy
Number of subjects: 0
Study: 4039588

Group type: EXPERIMENTAL
Intervention: Neobiphyllin (TPD) - 800 mg, infused for 20 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theophylline-ethylendiamine (TE) - 480 mg, short-infusion for 20 min
Number of subjects: 10
Study: 30913160

Group type: EXPERIMENTAL
Intervention: Appendicular BFR exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control exercise (CON exercise)
Number of subjects: 32
Study: 27796434

Group type: EXPERIMENTAL
Intervention: Probiotic Pearls™ Acidophilus (Pearls)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional hard‐shelled gelatin capsule
Number of subjects: 12
Study: 25601917

Group type: COMPARATOR
Intervention: No VTE prophylaxis (Group A)
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose unfractionated heparin (LDUH) 125 U/kg per day in three divided doses (Group B)
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) 6000 IU once a day (Group C)
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: LMWH 4000 IU twice daily (Group D)
Number of subjects: 2196
Study: 23571688

Group type: EXPERIMENTAL
Intervention: Immediate full weight-bearing for 3 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Partial weight-bearing for 3 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups at 5 years
Number of subjects: 39
Study: 20705373

Group type: EXPERIMENTAL
Intervention: n-3 PUFA 1 g daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 40
Study: 19389558

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1058
Study: 16643226

Group type: EXPERIMENTAL
Intervention: LCT/MCT propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: LCT propofol
Number of subjects: 50
Study: 15575002

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11245321

Group type: EXPERIMENTAL
Intervention: 2 g cefotiam (study group, n=76)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No prophylaxis (control group, n=70)
Number of subjects: 146
Study: 9730793

Group type: EXPERIMENTAL
Intervention: MDPI (beclomethasone dipropionate) 400 microgram twice daily
Number of subjects: 133

Group type: COMPARATOR
Intervention: MDI-spacer (beclomethasone dipropionate) 400 microgram twice daily
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: MDPI
Number of subjects: 133

Group type: COMPARATOR
Intervention: MDI-spacer
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: MDPI and MDI-spacer
Number of subjects: 133
Study: 8044729

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate with fluphenazine HCl i.m.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluphenazine decanoate depot injection used alone
Number of subjects: 0
Study: 3155318

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nicardipine and Nifedipine
Number of subjects: 12
Study: 30137607

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction for Breast Cancer (MBSR[BC]) program
Number of subjects: 185

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 185
Study: 27773708

Group type: EXPERIMENTAL
Intervention: Provider-targeted intervention to increase LARC access
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1500
Study: 26158894

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 23849501

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22416440

Group type: EXPERIMENTAL
Intervention: Standard treatment plus ivabradin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 49
Study: 19453578

Group type: EXPERIMENTAL
Intervention: Opioid analgesia
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 16735696

Group type: EXPERIMENTAL
Intervention: pegylated interferon‐alpha (IFN‐alpha) and ribavirin
Number of subjects: 20
Study: 15519705

Group type: EXPERIMENTAL
Intervention: Hib vaccination (1 dose)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Hib vaccination (2 doses)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Hib vaccination (3 doses)
Number of subjects: 389
Study: 10938566

Group type: EXPERIMENTAL
Intervention: Quantum Companion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9300509

Group type: EXPERIMENTAL
Intervention: Brief psychological intervention based on cognitive behavioural principles, including individualized information and discussion session by a specially trained cardiac nurse, handout, cassette providing information and advice, and telephone follow-up.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, but implied to be patients receiving standard care without the intervention.
Number of subjects: 0
Study: 10128359

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) administered in PVC containers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) administered in glass containers
Number of subjects: 20
Study: 3310905

Group type: EXPERIMENTAL
Intervention: Combination of prochlorperazine, metoclopramide and dexamethasone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide and dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoclopramide and dexamethasone on days 2‐7
Number of subjects: 40
Study: 30104307

Group type: EXPERIMENTAL
Intervention: 10TT intervention (habit-based advice for weight control)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 537

Group type: COMPARATOR
Intervention: 10TT intervention vs usual care
Number of subjects: 537
Study: 26840331

Group type: EXPERIMENTAL
Intervention: Resveratrol (200 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (200 mg/day)
Number of subjects: 19
Study: 24432995

Group type: EXPERIMENTAL
Intervention: Tianqi capsule for 12 months
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 420
Study: 23899039

Group type: EXPERIMENTAL
Intervention: Three-monthly monitoring
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Six-monthly monitoring
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Preference group (self-selected monitoring frequency)
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Randomised patients (not preferring a specific frequency)
Number of subjects: 2215
Study: 19912490

Group type: EXPERIMENTAL
Intervention: Intracavernous injection (ICI) of alprostadil 20 microgram
Number of subjects: 60

Group type: COMPARATOR
Intervention: Audio-visual sexual stimulation (AVSS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AVSS plus ICI
Number of subjects: 60
Study: 19138002

Group type: EXPERIMENTAL
Intervention: Diffractive MFIOL (Tecnis Multifocal)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Refractive MFIOL (ReZoom)
Number of subjects: 100
Study: 16968572

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% ophthalmic solution (Travatan)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Latanoprost 0.005% (Xalatan)
Number of subjects: 62
Study: 15299057

Group type: EXPERIMENTAL
Intervention: SKA-M (1 field of view)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: SKA-S
Number of subjects: 11

Group type: COMPARATOR
Intervention: Patlak analysis
Number of subjects: 11
Study: 11228598

Group type: EXPERIMENTAL
Intervention: 60% oxygen for ca. 10 min at 15 L/min by a face mask (treatment group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No oxygen supplementation (control group)
Number of subjects: 41
Study: 9310010

Group type: EXPERIMENTAL
Intervention: 600 mg isoniazid (INH)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 18.75 mg isoniazid (INH)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 300 mg isoniazid (INH)
Number of subjects: 105

Group type: COMPARATOR
Intervention: rifampin
Number of subjects: 105
Study: 8242574

Group type: EXPERIMENTAL
Intervention: Three-part structured pain education program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 40
Study: 3749007

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum thiocyanate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk score based on the Framingham Study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression coefficients for CHD and total mortality endpoints
Number of subjects: 0
Study: 30950208

Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26984227

Group type: EXPERIMENTAL
Intervention: Dietary patterns in Puerto Rican breast cancer survivors
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dietary patterns in Mexican-American breast cancer survivors
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DASH-style diet adherence score
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overweight/obesity prevalence
Number of subjects: 45
Study: 25847979

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Revascularization strategy (CABG)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Revascularization strategy (Percutaneous Coronary Intervention)
Number of subjects: 1800
Study: 23691692

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate maintenance infusion of 2 g/hour
Number of subjects: 60

Group type: COMPARATOR
Intervention: Magnesium sulfate maintenance infusion of 1 g/hour
Number of subjects: 60
Study: 21910336

Group type: EXPERIMENTAL
Intervention: Xunxi No. 1 intervention with radiotherapy for 20 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study: 19773098

Group type: EXPERIMENTAL
Intervention: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine without aluminum hydroxide adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine with aluminum hydroxide adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine
Number of subjects: 0
Study: 17522559

Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole (second injection)
Number of subjects: 3
Study: 14754783

Group type: EXPERIMENTAL
Intervention: Supervised benzodiazepine withdrawal program
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Supervised withdrawal plus cognitive behavior therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 76
Study: 11719664

Group type: EXPERIMENTAL
Intervention: urokinase plus abciximab
Number of subjects: 70

Group type: COMPARATOR
Intervention: urokinase alone
Number of subjects: 70
Study: 9117178

Group type: EXPERIMENTAL
Intervention: Living food, a form of uncooked vegan diet rich in lactobacilli
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ordinary omnivorous diets
Number of subjects: 43
Study: 8482933

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 417
Study: 2950148

Group type: EXPERIMENTAL
Intervention: Tetracycline 1 gram/day for 6 months plus topical therapy (benzoyl peroxide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (2 mg cyproterone acetate plus 50 micrograms ethinyl estradiol; spironolactone 100 mg twice daily; isotretinoin 1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 0
Study: 31851382

Group type: EXPERIMENTAL
Intervention: Modeled Practice
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study: 30528676

Group type: EXPERIMENTAL
Intervention: PF-04457845 (4 mg per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 28049937

Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx) training protocol (callisthenic exercises and walking in a heated pool for 1 h, three times weekly for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (maintaining habitual activities)
Number of subjects: 44
Study: 26527774

Group type: EXPERIMENTAL
Intervention: 64 Gy
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: 70 Gy
Number of subjects: 344
Study: 23669629

Group type: COMPARATOR
Intervention: Transdermal nicotine (placebo-controlled trial)
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (patch vs spray, open-label trial)
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Bupropion (placebo-controlled trial)
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: No lapse during the first week (across all trials)
Number of subjects: 1649
Study: 21080201

Group type: EXPERIMENTAL
Intervention: Chemotherapy (vinca alkaloids, taxanes, or platina derivatives)
Number of subjects: 152
Study: 19333153

Group type: EXPERIMENTAL
Intervention: Combination of morphine 0.5 mg and clonidine 100 microg (CMC)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Preservative free morphine 0.5 mg (MOR)
Number of subjects: 85
Study: 16697968

Group type: EXPERIMENTAL
Intervention: GnRH analogue (GnRH-a) injections during cyclophosphamide therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: No injection of GnRH analogue (GnRH-a) during cyclophosphamide therapy
Number of subjects: 63
Study: 14599857

Group type: EXPERIMENTAL
Intervention: Flexible Ralstron applicator
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rigid geometry Rotterdam applicator
Number of subjects: 50
Study: 10758454

Group type: EXPERIMENTAL
Intervention: Clonidine 6 microg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg kg‐1
Number of subjects: 40
Study: 8993085

Group type: EXPERIMENTAL
Intervention: Venlafaxine (maximum dose 225 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study: 1479658

Group type: EXPERIMENTAL
Intervention: Nerve blocks (Group A, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No nerve blocks (Group B, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Crying-group (n = 9)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calm-group (n = 31)
Number of subjects: 40
Study: 2865714

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age-related induction
Number of subjects: 0
Study: 30659771

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dosage regimen and formulations
Number of subjects: 0
Study: 29668978

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir + lamivudine
Number of subjects: 266

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir + 2NRTI
Number of subjects: 266
Study: 26663715

Group type: EXPERIMENTAL
Intervention: TDF/FTC + EFV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TDF/FTC + ATV/r
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABC/3TC + EFV
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABC/3TC + ATV/r
Number of subjects: 0
Study: 24559218

Group type: EXPERIMENTAL
Intervention: Enhanced multi-disciplinary teams (EMDTs)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study: 22541809

Group type: EXPERIMENTAL
Intervention: Push method
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pull method
Number of subjects: 72
Study: 20609968

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 546
Study: 18514318

Group type: EXPERIMENTAL
Intervention: Overall average RNFL thickness
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Inferior quadrant RNFL thickness
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Superior quadrant RNFL thickness
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combination of overall, inferior, and superior quadrant RNFL thicknesses
Number of subjects: 89
Study: 16583592

Group type: EXPERIMENTAL
Intervention: Colgate Total
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate Total plus Whitening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PerioGard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colgate Regular Dental Cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorigard
Number of subjects: 0
Study: 11796444

Group type: EXPERIMENTAL
Intervention: BDP, 800 microg/d
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: BDP, 1,500 microg/d
Number of subjects: 68
Study: 10380867

Group type: EXPERIMENTAL
Intervention: Error-detection approach in 3-year-olds
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Evaluation of puppet's behavior by 3-year-olds
Number of subjects: 3
Study: 8696715

Group type: EXPERIMENTAL
Intervention: Cisplatin-mitomycin-vinorelbine (VNB group, n = 114)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Cisplatin-mitomycin-vindesine (VDS group, n = 113)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Cisplatin-mitomycin-vinorelbine (VNB group)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Cisplatin-mitomycin-vindesine (VDS group)
Number of subjects: 227
Study: 1508114

Group type: EXPERIMENTAL
Intervention: Intravenous and intracoronary therapy with streptokinase
Number of subjects: 206

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Early reperfusion (less than or equal to 3.5 h)
Number of subjects: 206

Group type: COMPARATOR
Intervention: CABG patients
Number of subjects: 206

Group type: COMPARATOR
Intervention: PTCA patients
Number of subjects: 206

Group type: COMPARATOR
Intervention: Patients without reperfusion
Number of subjects: 206
Study: 6389014

Group type: EXPERIMENTAL
Intervention: Flupirtine maleate (100 mg, oral doses, up to 4 doses per day for 5 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paracetamol (1 g, oral doses, up to 4 doses per day for 5 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flupirtine maleate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 40
Study: 31621643

Group type: EXPERIMENTAL
Intervention: DEC (work intervals with a fast start)
Number of subjects: 11

Group type: COMPARATOR
Intervention: TRAD (traditional session with constant speed)
Number of subjects: 11
Study: 29287749

Group type: EXPERIMENTAL
Intervention: Andecaliximab (400 mg) administered every 2 weeks for a total of 3 intravenous infusions.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo administered every 2 weeks for a total of 3 intravenous infusions.
Number of subjects: 18
Study: 26550689

Group type: EXPERIMENTAL
Intervention: Mitral-valve repair
Number of subjects: 251

Group type: COMPARATOR
Intervention: Mitral-valve replacement
Number of subjects: 251
Study: 25020152

Group type: EXPERIMENTAL
Intervention: Internet-based prevention program
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Group-based prevention program
Number of subjects: 107

Group type: COMPARATOR
Intervention: Educational video and educational brochure
Number of subjects: 107